Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetrelimab + Daratumumab in Relapsed/Refractory Multiple Myeloma
NCT03357952Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2017
- Primary completion
- Oct 2018
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 3
01
Overview
A Phase 3 trial of cetrelimab in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started Nov 2017; status: completed.
02
Drugs
cetrelimab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03357952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03357952.